Miriam Soares

Mrs. Miriam Soares


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2024 in Brain Sciences
Verified
Journal Article
Open access
PDF file
RBRenata Montes Garcia Barbosa
Renata Montes Garcia Barbosa
MSMiriam Soares
Miriam Soares
DPDenise Maria Meneses Cury Portela
Denise Maria Meneses Cury Portela
TGThiago Gonçalves Guimarães
Thiago Gonçalves Guimarães
RCRubens Gisbert Cury
Rubens Gisbert Cury
Deep Brain Stimulation (DBS) is an effective treatment option for patients with dopaminergic complications of Parkinson’s disease (PD) and drug-refractory PD tremor. However, DBS and its indications can be challenging, and they are not often debated in the medical community. Through a critical narrative review, the objective of this paper is to improve the comprehension of DBS indications and help to solve the puzzle that this process can be. Proper patient selection is the first step for a good surgical outcome. In this review, then, relevant considerations are discussed, involving PD genes, PD phenotypes, indications of early stages, non-motor symptoms, neuroimaging predictors, comorbidities, and age. Individualized approaches are encouraged, including clinical and radiological factors. Social support during the whole follow-up and expectations alignment are necessary through this process and are also debated.

20 June 2024 in Toxins
Verified
Journal Article
Open access
PDF file
JSJulia Carvalhinho Carlos de Souza
Julia Carvalhinho Carlos de Souza
AFAnanda Carolina Moraes Falcone
Ananda Carolina Moraes Falcone
RBRenata Montes Garcia Barbosa
Renata Montes Garcia Barbosa
MSMiriam Soares
Miriam Soares
RMRenato P. Munhoz
Renato P. Munhoz
RCRubens Gisbert Cury
Rubens Gisbert Cury
Deep Brain Stimulation (DBS) is a recognized treatment for different dystonia subtypes and has been approved by the Food and Drug Administration (FDA) since 2003. The European Federation of Neurological Societies (EFNS) and the International Parkinson and Movement Disorders Society (MDS) recommend DBS for dystonia after failure of botulinum toxin (BoNT) and other oral medications for dystonia treatment. In addition, several long-term studies have demonstrated the continuous efficacy of DBS on motor and quality of life (QoL) scores. However, there are only a few reports comparing the overall impact of surgical treatment in BoNT protocols (e.g., dosage and number of selected muscles before and after surgery). This retrospective multicenter chart-review study analyzed botulinum toxin total dosage and dosage per muscle in 23 dystonic patients before and after DBS surgery. The study’s primary outcome was to analyze whether there was a reduction in BoNT dosage after DBS surgery. The mean BoNT dosages difference between baseline and post-surgery was 293.4 units for 6 months, 292.6 units for 12 months, and 295.2 units at the last visit. The median total dose of BoNT in the preoperative period was 800 units (N = 23). At the last visit, the median was 700 units (p = 0.05). This represents a 12.5% reduction in BoNT median dosage. In conclusion, despite the limitations of this retrospective study, there was a significant reduction in BoNT doses after DBS surgery in patients with generalized dystonia.

30 December 2021 in Practical Neurology
Verified
Journal Article
Closed access
PDF file
MSMiriam Soares
Miriam Soares
OLOtávio Gomes Lins
Otávio Gomes Lins
JCJosé Ronaldo Lima de Carvalho
José Ronaldo Lima de Carvalho
CSCláudia Cristina de Sá
Cláudia Cristina de Sá
VLVanessa Van der Linden
Vanessa Van der Linden
ACAnna Paula Paranhos Miranda Covaleski
Anna Paula Paranhos Miranda Covaleski
Allgrove syndrome is an autosomal recessive disease mostly caused by mutations in the AAAS gene. It has variable clinical features but its cardinal features comprise the triad of achalasia, alacrimia and adrenal insufficiency. It typically develops during the first decade of life, but some cases have second and third decades onset. We describe a 25-year-old woman with Allgrove syndrome who had progressive amyotrophy, achalasia, dry eyes and adrenal insufficiency since childhood. Awareness of its neurological manifestations and multisystem features helps to shorten the time for diagnosis and allow appropriate symptomatic treatment.

7 March 2024 in Practical Neurology
Verified
Journal Article
Closed access
PDF file
MSMiriam Soares
Miriam Soares
JPJacy Bezerra Parmera
Jacy Bezerra Parmera
MBMarcos Eugênio Ramalho Bezerra
Marcos Eugênio Ramalho Bezerra
RCRubens Gisbert Cury
Rubens Gisbert Cury
An 18-year-old man had episodes of severe generalised dystonia, from aged 7 months and becoming progressively more frequent. He also had gradually developed interictal limb dystonia. He was initially diagnosed with paroxysmal kinesigenic dyskinesia but he did not improve with several medications. A levodopa trial led to levodopa-induced dyskinetic movements. However, a lower titration of 25 mg of levodopa two times per day substantially improved his motor features and quality of life. Laboratory investigations and MR scans of the brain were unremarkable. Whole-exome sequencing identified a pathogenic variant in the ATP1A3 gene. The ATP1A3-spectrum disorders include non-classical phenotypes such as paroxysmal dystonic attacks. A response to dopamine response is unusual in these disorders. This case highlights the importance of levodopa trials in early-onset dystonia cases.

5 March 2026 in Movement Disorders Clinical Practice
Verified
Journal Article
Open access
MSMiriam Soares
Miriam Soares
JPJacy Bezerra Parmera
Jacy Bezerra Parmera
PRPedro Augusto Sampaio Rocha-Filho
Pedro Augusto Sampaio Rocha-Filho
Background: Hemifacial spasm (HFS) is a chronic neurological disorder characterized by involuntary contractions of facial muscles. Traditionally regarded as a motor condition, HFS encompasses a spectrum of non‐motor symptoms that are often overlooked but significantly affect patients’ quality of life. Objectives: This systematic review aimed to synthesize current evidence on the prevalence and clinical relevance of non‐motor manifestations in HFS. Methods: A systematic search was conducted across PubMed, Cochrane, and EMBASE databases up to June 29, 2025, following PRISMA guidelines. Eligible studies included cross‐sectional, cohort, case–control, and case series designs reporting pain, psychiatric symptoms, or sleep disturbances in HFS. Risk of bias was assessed using the Joanna Briggs Institute critical appraisal tools according to study design. Results: Twenty‐two studies met inclusion criteria. Headache was reported in varying frequencies, ranging from 24.2% to 60% of cases, and facial pain in 33.3%, both frequently improving after botulinum toxin (BoNT) therapy. Psychiatric comorbidities were prevalent, with depression and anxiety reported in 5.7% to 29% and 9.1% to 19.5% of patients, respectively. Sleep disorders, mainly insomnia, occurred up to three times more often in HFS patients than in controls. BoNT therapy demonstrated beneficial effects beyond motor control, reducing pain, anxiety, and depressive symptoms. Conclusion: HFS is a multidimensional disorder with substantial non‐motor burden. Recognition and management of pain, psychiatric, and sleep‐related symptoms are essential to improving treatment outcomes and overall patient well‐being.

28 August 2025 in Movement Disorders Clinical Practice
Verified
Journal Article
Closed access
RMRaissa Josefa Pereira de Moura
Raissa Josefa Pereira de Moura
DQDanielle Cleide da Silva Lima Queiroz
Danielle Cleide da Silva Lima Queiroz
RMRenata Amaral Andrade Mendonça
Renata Amaral Andrade Mendonça
RBRenata Montes Garcia Barbosa
Renata Montes Garcia Barbosa
MSMiriam Soares
Miriam Soares